Crescent Biopharma Inc. (CBIO) — RQD Stock Rating Cockpit

The Roarable RQD rating assigns a score of 29 out of 100, a letter grade of E, and a verdict label of "Roarable Strong Sell — Forensic Risk / Avoid." Per the Roarable RQD rating, the five pillars score as follows:

• Fundamental Cash Engine (5 / 20): Reflects an ROIC of -35% and an FCF yield of -13.86%. For a prospective investor, this indicates the business is not currently generating cash returns on invested capital, and free cash flow is negative relative to the market value.
• Whale 13F Flow (5 / 20): Covers institutional accumulation and options positioning. The source data does not provide the underlying 13F holdings detail, so the score can be read only as a weak institutional signal.
• Insider Conviction (3 / 20): Based on SEC Form 4 and Congressional PTR cluster flow. The low score signals limited evidence of insider conviction in the stock.
• Macro Regime Fit (3 / 20): Reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broader market, offering no defensive cushion, while the low score signals weak alignment with the current macro regime.
• Forensic Balance Sheet (13 / 20): The strongest pillar, reflecting an Altman Z-Score of 6.36, a Piotroski F-Score of 3/9, and Debt/Equity of 0.5. The Altman figure points to a financially sturdier balance sheet than the cash-flow pillars, while the weak Piotroski score signals deteriorating fundamental quality.

Taken together, the pillar scores show that the balance sheet is the only area of relative strength; cash generation, institutional and insider signals, and macro fit all score poorly. For a prospective investor evaluating the stock today, the rating implies that upside depends on a turnaround in operating economics that the current data does not yet show, and that valuation cannot be anchored to earnings or cash flow because those measures are negative or unavailable. This is an analytical reading of the rating, not personalized financial advice.

Per the SEC financials, operating margin is -60% and gross margin is 0%, while net margin is reported at 1.4% per the market data section, a figure that diverges sharply from the negative operating income and should be treated with caution. ROIC is -35% per the market data. The Roarable RQD rating cites an Altman Z-Score of 6.36, a Piotroski F-Score of 3/9, and Debt/Equity of 0.5, indicating a balance sheet with relatively low leverage but weak fundamental quality signals.

Per the recent news and catalysts section, the feed contains six items, all tagged with a YELLOW light and MARKET WIRE impact label:

• Inducement award grants announced (Yahoo Finance).
• Estimates coverage (TradingView).
• Stifel reiterated a Buy rating with a $28 target (Investing.com).
• A notice that three talks will be webcast live, with replays available for 90 days (Stock Titan).
• H.C. Wainwright reiterated a buy rating (Investing.com).
• H.C. Wainwright & Co. reiterated a Buy rating with a $36 price target (TradingView).

Key catalysts are the reiterated analyst Buy ratings and their stated price targets. Risk watch items include the negative operating income and free cash flow reported in the financials. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

• What is the path to positive operating income, given FY 2025 operating income of $-152.6M against revenue of $10.8M?
• Which specific revenue sources generated the FY 2025 revenue, and how durable are they?
• What explains the reported 1.4% net margin when operating income is deeply negative?
• What debt obligations sit behind the Debt/Equity figure, given that debt is reported as N/A in the financials?
• What is the consensus rating and price target distribution beyond the two reiterated ratings in the news feed?